| 1. Malerba M, Ragnoli B. (2008) Ambroxol in the 21st century: pharmacological and clinical update.. Expert Opin Drug Metab Toxicol, 4 (8): (1119-29). [PMID:18680446] [10.1021/op500134e] |
| 2. Maegawa GH, Tropak MB, Buttner JD, Rigat BA, Fuller M, Pandit D, Tang L, Kornhaber GJ, Hamuro Y, Clarke JT et al.. (2009) Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.. J Biol Chem, 284 (35): (23502-16). [PMID:19578116] [10.1021/op500134e] |
| 3. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A et al.. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.. N Engl J Med, 361 (17): (1651-61). [PMID:19846850] [10.1021/op500134e] |
| 4. Luan Z, Li L, Higaki K, Nanba E, Suzuki Y, Ohno K. (2013) The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice.. Brain Dev, 35 (4): (317-22). [PMID:22682976] [10.1021/op500134e] |
| 5. Zimran A, Altarescu G, Elstein D. (2013) Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.. Blood Cells Mol Dis, 50 (2): (134-7). [PMID:23085429] [10.1021/op500134e] |
| 6. Bendikov-Bar I, Maor G, Filocamo M, Horowitz M. (2013) Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.. Blood Cells Mol Dis, 50 (2): (141-5). [PMID:23158495] [10.1021/op500134e] |
| 7. McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, Foltynie T, Cooper JM, Abramov AY, Gegg M et al.. (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.. Brain, 137 (Pt 5): (1481-95). [PMID:24574503] [10.1021/op500134e] |
| 8. Migdalska-Richards A, Daly L, Bezard E, Schapira AH. (2016) Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.. Ann Neurol, 80 (5): (766-775). [PMID:27859541] [10.1021/op500134e] |
| 9. Yang SY, Beavan M, Chau KY, Taanman JW, Schapira AHV. (2017) A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.. Stem Cell Reports, 8 (3): (728-742). [PMID:28216145] [10.1021/op500134e] |
| 10. Migdalska-Richards A, Schapira AH. (2016) The relationship between glucocerebrosidase mutations and Parkinson disease.. J Neurochem, 139 Suppl 1 (13): (77-90). [PMID:26860875] [10.1021/op500134e] |
| 11. Narita A, Shirai K, Itamura S, Matsuda A, Ishihara A, Matsushita K, Fukuda C, Kubota N, Takayama R, Shigematsu H et al.. (2016) Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study.. Ann Clin Transl Neurol, 3 (3): (200-15). [PMID:27042680] [10.1021/op500134e] |
| 12. Migdalska-Richards A, Ko WKD, Li Q, Bezard E, Schapira AHV. (2017) Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.. Synapse, 71 (7): (1755-70). [PMID:28295625] [10.1021/op500134e] |
| 13. Cazan D, Klimek L, Sperl A, Plomer M, Kölsch S. (2018) Safety of ambroxol in the treatment of airway diseases in adult patients.. Expert Opin Drug Saf, 17 (12): (1211-1224). [PMID:30372367] [10.1021/op500134e] |
| 14. Silveira CRA, MacKinley J, Coleman K, Li Z, Finger E, Bartha R, Morrow SA, Wells J, Borrie M, Tirona RG et al.. (2019) Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.. BMC Neurol, 19 (1): (20). [PMID:30738426] [10.1021/op500134e] |
| 15. Bouscary A, Quessada C, Mosbach A, Callizot N, Spedding M, Loeffler JP, Henriques A. (2019) Ambroxol Hydrochloride Improves Motor Functions and Extends Survival in a Mouse Model of Familial Amyotrophic Lateral Sclerosis.. Front Pharmacol, 10 (13): (883). [PMID:31447678] [10.1021/op500134e] |
| 16. Mullin S, Smith L, Lee K, D'Souza G, Woodgate P, Elflein J, Hällqvist J, Toffoli M, Streeter A, Hosking J et al.. (2020) Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.. JAMA Neurol, 77 (4): (427-434). [PMID:31930374] [10.1021/op500134e] |
| 17. Olaleye OA, Kaur M, Onyenaka CC. (2020) Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2.. bioRxiv, 71 (13): (1755-70). [PMID:32995775] [10.1101/2020.09.13.295691] |
| 18. O'Brien JT, Chouliaras L, Sultana J, Taylor JP, Ballard C, RENEWAL Study Group. (2022) RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia-an international Delphi consensus.. Alzheimers Res Ther, 14 (1): (169). [PMID:36369100] [10.1021/op500134e] |
